Gelonghui, April 15 | Sinopharm Hyundai (600420.SH) announced that its wholly-owned subsidiary Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. has received the “Drug Registration Certificate” for englizine tablets approved and issued by the State Drug Administration. Empagliflozin reduces the ability of the kidneys to recycle glucose back into the bloodstream and excretes sugar from the body through urine, which helps reduce patients' blood sugar levels.
国药现代(600420.SH)：恩格列净片获得药品注册证书
Sinopharm Hyundai (600420.SH): Empagliflozin tablets obtained drug registration certificate
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.